Benzinga  Mar 15  Comment 
Following the SOLO-2 trial results surpassing expectations, Wedbush’s David Nierengarten stated that the data demonstrated “similar top-line efficacy for Lynparza as that achieved by niraparib in the NOVA study.” The analyst reiterated an...
The Hindu Business Line  Feb 22  Comment 
The Ministry of Defence has signed a contract with NOVA Integrated Systems Limited, a subsidiary of Tata Advanced Systems Limited to execute Indian Navy’s Surface Surveillance Radar project. The S...
Benzinga  Oct 10  Comment 
Barclays found that TESARO Inc (NASDAQ: TSRO)'s final stage results on NOVA and its indication to pursue a wider label for the drug means a setback for Myriad Genetics, Inc. (NASDAQ: MYGN) and its myChoice HRD. As a result, Myriad stock traded...
Forbes  Aug 2  Comment 
Weekly App Roundup for Tuesday, August 2nd, 2016: Blitzify, Odell Moji, NOVA Black Holes And Guardian Circle
Benzinga  Jun 29  Comment 
TESARO Inc (NASDAQ: TSRO) revealed the Phase 3 NOVA trial of niraparib successfully achieved its primary endpoint of progression-free survival (PFS). The study illustrated that niraparib significantly prolonged PFS compared to control among...
The Hindu Business Line  Jan 22  Comment 
Chapter 1 Akilan opened his eyes. Then he closed them, and opened them again. The second time, he looked around — with the blank stare of a person whose thoughts have been wiped clean, trying to f...
Forbes  Aug 26  Comment 
"There is so much evidence, none of which shows any link between vaccines and autism, that you have to say, "Enough!"
Benzinga  Jul 8  Comment 
Intersect ENT, Inc. (Nasdaq: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the enrollment of the first patient in the company's pivotal study of its latest...
TechCrunch  Jan 8  Comment 
 Edward Snowden says in a new interview with NOVA Next that the U.S. government wrongly promotes cyber offense strategies at the expense of weakening the system and leaving it open to cyber attacks from the black market. “We’re creating a...
OilVoice  Nov 4  Comment 
TransCanada Corporation TSXTRP NYSETRP announce that its whollyowned subsidiary NOVA Gas Transmission Ltd. NGTL will contract approximately 4.0 billion cubic feet per day Bcfd of firm ne


Headquartered in Chicago, Illinois, NovaMed, Inc. (NOVA), formerly NovaMed Eyecare, Inc., is an emerging healthcare services company engaged in the operation of ambulatory surgery centers (ASCs) and the provision of optical products and services to eye-care professionals. Founded in 1995 and floated in 1999, the company was originally a provider of physician practice management services to eye-care professionals, and later entered the Laser Vision Correction (LVC) market. Since 2001, the company's primary focus has been on the acquisition, development, and operation of ASCs in partnership with healthcare professionals. The company currently has ownership interests in 34 ASCs located in 18 states, with the majority located adjacent to or near the physicians' practices. Most of these ASCs are single-specialty ophthalmic surgical facilities, where eye-care professionals perform surgical procedures, primarily cataract and refractive surgery (laser vision correction). The company also has a nonexclusive supply agreement with Alcon Laboratories, Inc., which allows NOVA to procure and utilize excimer lasers and other equipment manufactured by Alcon. As a result, the company also provides excimer lasers and other services to eye-care professionals for their use in performing laser vision correction surgery under fixed-site laser agreements. In addition, NovaMed also owns and operates optical laboratories (manufacture and sale of corrective lenses and eyeglasses), an optical-products purchasing organization (eyeglass frames and contact lenses purchased from other manufacturers), and a marketing products and services business. In 2004, the two broad divisions of ASC and Product Sales represented 72% and 28% of total revenues, respectively.

Cost containment, driven by ongoing pressure from the third-party payors, has fueled significant growth of surgical procedures performed in outpatient settings. A key driver of the growth has been the strong physician and patient preference for non-hospital locations, which provide easy access to the frail and the elderly, as well as more control over scheduling for the healthcare professional. Ophthalmology is the largest single type of outpatient surgery, representing approximately 27% of all outpatient surgeries performed in 2000. We believe ASC industry fundamentals remain attractive given the increasing focus on conditions afflicting the elderly such as cataracts. We note that cataract surgery accounted for an estimated 2.7 million of surgical procedures performed in 2002. At the company level, NOVA's practice management expertise and excess ASC capacity provides an opportunity to expand into allied high-growth surgical specialty areas. For instance, these may include other specialty areas, such as orthopedics and podiatry. Typically, NOVA owns approximately 65% of the ASC with the healthcare professional owning the balance. Given that an ASC's principal revenue source is the "facility fee" charged for surgical procedures performed in the center, we believe NOVA's partnering with ophthalmologists aligns common goals to increase volume and productivity while reducing capital outlay for both parties.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki